IDEXX Laboratories (NASDAQ:IDXX) Sets New 1-Year Low - Here's Why

Key Points

• IDEXX Laboratories shares hit a new 52-week low, falling to $515.86 and trading below both their 50-day and 200-day moving averages.
• Analyst sentiment remains moderately positive, with six Buy ratings and four Holds and a consensus price target of $747, despite recent price-target cuts and downgrades.
• The company exceeded quarterly expectations, reporting $4.27 in EPS and $1.22 billion in revenue, while revenue increased 9.7% year over year.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as $515.86 and last traded at $519.3270, with a volume of 24987 shares traded. The stock had previously closed at $520.21.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of research analyst reports. Weiss Ratings cut shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday, August 27th. Barclays decreased their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research note on Tuesday, August 11th. UBS Group upped their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Citigroup increased their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $747.00.

IDEXX Laboratories Price Performance

The firm's 50 day moving average price is $558.13 and its two-hundred day moving average price is $568.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock has a market cap of $41.03 billion, a PE ratio of 36.59, a P/E/G ratio of 2.86 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the prior year, the company posted $3.50 EPS. IDEXX Laboratories's revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $25,000. SHP Wealth Management purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $26,000. Elevation Wealth Partners LLC increased its holdings in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after acquiring an additional 32 shares during the period. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Finally, WealthCollab LLC bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion-animal veterinary market, offering laboratory and in-clinic diagnostic testing, analyzers, consumables, digital imaging solutions and veterinary practice-management software. Its products help veterinarians diagnose and monitor diseases, manage patient records and improve clinical workflows.

IDEXX also provides testing products and services for livestock and poultry health, as well as microbiology testing solutions for water quality.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.